[Injection Therapy of Diabetes]

Overview

Journal Wien Klin Wochenschr

Publisher Springer

Specialty General Medicine

Date 2023 Apr 26

PMID 37101024

Authors

Monika Lechleitner

Michael Roden

Raimund Weitgasser

Bernhard Ludvik

Peter Fasching

Friedrich Hoppichler

Alexandra Kautzky-Willer

Guntram Schernthaner

Rudolf Prager

Susanne Kaser

T C Wascher

Affiliations

Soon will be listed here.

Abstract

The present article is a recommendation of the Austrian Diabetes Association for the practical use of injection therapy (GLP1-receptor agonists and insulin) in type 2 diabetes.

References

Singh S, Wright Jr E, Kwan A, Thompson J, Syed I, Korol E . Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2016; 19(2):228-238. PMC: 5299485. DOI: 10.1111/dom.12805. View

Frias J . Prioritising injectable therapies in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2019; 7(7):505-508. DOI: 10.1016/S2213-8587(19)30117-2. View

Alexopoulos A, Buse J . Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism. 2019; 98:104-111. PMC: 6690751. DOI: 10.1016/j.metabol.2019.06.012. View

Abd El Aziz M, Kahle M, Meier J, Nauck M . A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2016; 19(2):216-227. DOI: 10.1111/dom.12804. View

Buse J, Wexler D, Tsapas A, Rossing P, Mingrone G, Mathieu C . 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019; 43(2):487-493. PMC: 6971782. DOI: 10.2337/dci19-0066. View

Blair H, Keating G . Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus. Drugs. 2016; 76(3):363-74. DOI: 10.1007/s40265-016-0541-z. View

Ludvik B, Giorgino F, Jodar E, Frias J, Lando L, Brown K . Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021; 398(10300):583-598. DOI: 10.1016/S0140-6736(21)01443-4. View

Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews D, Tsapas A . Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022; 65(8):1251-1261. PMC: 9112245. DOI: 10.1007/s00125-022-05715-4. View

Heise T, Linnebjerg H, Coutant D, LaBell E, Zijlstra E, Kapitza C . Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. Diabetes Obes Metab. 2020; 22(10):1789-1798. PMC: 7540588. DOI: 10.1111/dom.14094. View

10.

Davis A, Kuriakose J, Clements J . Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. Clin Pharmacokinet. 2018; 58(4):421-430. DOI: 10.1007/s40262-018-0696-8. View

11.

Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K . (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020; 11:CD005613. PMC: 8095010. DOI: 10.1002/14651858.CD005613.pub4. View

12.

Bradley M, Chillarige Y, Lee H, Wu X, Parulekar S, Muthuri S . Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin. JAMA Intern Med. 2021; 181(5):598-607. PMC: 7922234. DOI: 10.1001/jamainternmed.2020.9176. View

13.

Lamos E, Younk L, Davis S . Concentrated insulins: the new basal insulins. Ther Clin Risk Manag. 2016; 12:389-400. PMC: 4790523. DOI: 10.2147/TCRM.S99855. View

14.

Ritzel R, Roussel R, Giaccari A, Vora J, Brulle-Wohlhueter C, Yki-Jarvinen H . Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab. 2017; 20(3):541-548. PMC: 5836995. DOI: 10.1111/dom.13105. View

15.

Rodacki M, Carvalho R, Zajdenverg L . The potential effect of ultra-long insulin degludec on glycemic variability. Diabetes Res Clin Pract. 2017; 133:92-103. DOI: 10.1016/j.diabres.2017.06.003. View

16.

Ritzel R, Roussel R, Bolli G, Vinet L, Brulle-Wohlhueter C, Glezer S . Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015; 17(9):859-67. PMC: 4676914. DOI: 10.1111/dom.12485. View

17.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L . Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825):1489-97. DOI: 10.1016/S0140-6736(12)60204-9. View

18.

Garber A, King A, Del Prato S, Sreenan S, Balci M, Munoz-Torres M . Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825):1498-507. DOI: 10.1016/S0140-6736(12)60205-0. View

19.

Marso S, McGuire D, Zinman B, Poulter N, Emerson S, Pieber T . Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017; 377(8):723-732. PMC: 5731244. DOI: 10.1056/NEJMoa1615692. View

20.

Zinman B, Marso S, Poulter N, Emerson S, Pieber T, Pratley R . Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2017; 61(1):48-57. PMC: 6002963. DOI: 10.1007/s00125-017-4423-z. View